Paul H Sugarbaker, MD, FACS, FRCS
PMP Pals' Network Annual International Conference
World renowned surgical oncologist, Dr Paul H Sugarbaker specializes in gastointestinal oncology, including the treatment of Appendix Cancer, Pseudomyxoma Peritonei, Mesothelioma and all Peritoneal Surface Malignancies
Dr Sugarbaker is co president of the 8th World Congress on PSMs
Surgical oncologists from around the world will meet this fall to exchange research focused on the treatment of Peritoneal Surface Malignancies
October 31-November 2, 2012
Berlin, Germany
Schedule a consultation with Dr Paul Sugarbaker
Paul H. Sugarbaker, MD, FACS, FRCS, Director, Program in Peritoneal Surface Malignancy
Washington Hospital Center
106 Irving St., NW, POB 3900
Washington, DC 20010 USA
Phone: (202) 877-3908 Fax: (202) 877-8602 Email: Paul.Sugarbaker@medstar.net
Practice Administrator: Ilse Sugarbaker
HITAC for Pseudomyxoma Peritonei and DMPM Therapy
Hyperthermic Intraoperative Thoracoabdominal Chemotherapy.
Sugarbaker PH, Chang D, Stuart OA.
Gastroenterol Res Pract. 2012;2012:623417. Epub 2012 May 10.
SourceWashington Hospital Center, Washington Cancer Institute, 106 Irving Street, NW, Suite 3900, Washington, DC 20010, USA.
Abstract
Cytoreductive surgery combined with hyperthermic intraperitoneal chemotherapy (HIPEC) is a treatment option for selected patients with pseudomyxoma peritonei (PMP) and diffuse malignant peritoneal mesothelioma (DMPM).
Tumor infiltration of the hemidiaphragm requiring partial resection occurs as a result of large volume and/or invasive disease at this anatomic site. Transmission of disease from abdomen to chest is a great danger in this group of patients.
From a prospective database, patients who had diaphragm resection and then hyperthermic thoracoabdominal chemotherapy (HITAC) as a component of a cytoreductive surgical procedure were identified.
Data from control patients receiving HIPEC or hyperthermic intrathoracic chemotherapy (HITOC) were analyzed for comparison. The morbidity, mortality, survival, and recurrence rate within the thoracic space were presented.
Thirty patients had partial resection of a hemidiaphragm as part of a cytoreductive surgical procedure that utilized HITAC. The pharmacologic benefit of intracavitary chemotherapy administration was documented with an area under the curve ratio of intracavitary concentration times time to plasma concentration times time of 27 ± 10 for mitomycin C and 75 ± 26 for doxorubicin. Comparing percent chemotherapy absorbed for a ninety-minute treatment showed the largest for HIPEC, then for HITAC, and lowest for HITOC. The incidence of grade 3 and 4 adverse events was 43%. There was no mortality.
Adjustments in the chemotherapy dose are not necessary with HITAC. The morbidity was high, the survival was acceptable, and intrathoracic recurrence was low.
PMID:22654899 PubMed - in process] PMCID:PMC3357938
Dr Sugarbaker's Honors, Awards and Society Memberships
Paul Sugarbaker, MD is a professor, investigator, and lectures throughout North America and internationally, earning numerous awards and citations. He is well known for his expertise in gastrointestinal oncology and colorectal cancer surgery and in rare diseases including pseudomyxoma peritonei, peritoneal mesothelioma, abdominal sarcomas, and peritoneal carcinomatosis.
Dr. Sugarbaker has pioneered specialty treatment procedures including cytoreductive surgery (CRS) with heated intraoperative intraperitoneal chemotherapy (HIPEC) and hyperthermia treatments using the Thermotron RF-8.
Dr Sugarbaker has published more than 780 scientific articles in peer-reviewed journals, numerous book chapters and textbooks. His textbook about sarcoma surgery has been translated into five languages.
Member of the American College of Surgeons
Member of University Surgeons
Member of International Association for Enterostomal Therapy
Member of American Surgical Association
Founding Member International Society of Regional Cancer Therapy Society of American Gastrointestinal Endoscopic Surgeons
E. T. Krementz Award for the best research development in 1997
Awarded the Doctor Honoris Causa at the Universite de Liege, Belgium in March 1999
Fellow ad eundem of The Royal College of Surgeons of England in September 1999
Distinguished Service Award by the American Society of Abdominal Surgeons in May 2001
Fellow at The Royal College of Physicians and Surgeons of Glasgow, Scotland in November 2003
Merium Ann Simone Distinguished Service Award - International Spirit of Life Foundation at Washington, DC in June 2006
Honorary Professor at Universidad Nacional de Cordoba, Argentina in November 2006
Member of four different editorial boards
Additional Training, Education & Research
1976-1986 Senior Investigator of the Surgery Branch at the National Cancer Institute, NIH in Bethesda, Maryland
1981-1986 served as Head of the Colorectal Cancer Section at the National Cancer Institute, NIH in Bethesda, Maryland
1986 appointed as the Director of Surgical Oncology at the Emory University School of Medicine in Atlanta, Georgia
1989-1993 Medical Director of the Washington Cancer Institute
1993-present Director, Program in Peritoneal Surface Malignancy at the Washington Cancer Institute
Courtesy of Washington Hospital Center
ASPSM
PSOGI
Dr Paul H Sugarbaker is the Secretary General of the PSOGI
Sugarbaker Oncology Associates
The Center for Surgical Oncology at the Washington Cancer Institute, Washington Hospital Center, in Washington, D.C. specializes in the surgical treatment of cancers of the gastrointestinal tract (appendix cancer, colon cancer, and rectal cancer); and other areas of the abdomen and pelvis.
International Events Featuring Dr Paul H Sugarbaker
Dr Paul Sugarbaker taught at El Instituto Nacional de Cancerologia in Tialpan, Mexico, April 26-27,2012
Dr Sugarbaker Teaches Surgical Oncologists in Mexico
HIPEC Conference Toluca Mexico
News story: Drs Sugarbaker and Esquivel bring HIPEC to Mexico
Source: PMP Pals' Network News June 2011
Dr Paul H Sugarbaker hosted a symposium...
Dr Paul H Sugarbaker hosted a CRS and HIPEC workshop at the Washington Hospital Center,on June 20 & 21, 2012.
Prior to the symposium, Dr Sugarbaker told PMP Pals,
"We will perform a live surgery including a full day of didactic teaching by world experts.
Dr Sugarbaker said, "The emphasis of this year's workshop is on 'proactive management.' If we can get patients with appendix malignancy, peritoneal mesothelioma, and colorectal cancer treated early with a small volume of disease, the long term results are superior and the quality of life issue less prominent.
Of course, if these treatments become more accepted for colorectal cancer patients with peritoneal metastases we are expecting approximately 15,000 new patients per year in the United States. Certainly, that will require many additional centers of excellence for CRS plus HIPEC."
Referring to PMP in particular, Dr H Sugarbaker tells PMP Pals, "Now there are are many 10-year and 20-year survivors of this rare disease. Definitely, a new chapter in the medical history of pseudomyxoma peritonei has been written."
Click here for more information about Dr Paul H Sugarbaker's research.
Gabriella conducted this interview with Dr Paul H Sugarbaker on March 30, 2012.
Prior to the symposium, Dr Sugarbaker told PMP Pals,
"We will perform a live surgery including a full day of didactic teaching by world experts.
Dr Sugarbaker said, "The emphasis of this year's workshop is on 'proactive management.' If we can get patients with appendix malignancy, peritoneal mesothelioma, and colorectal cancer treated early with a small volume of disease, the long term results are superior and the quality of life issue less prominent.
Of course, if these treatments become more accepted for colorectal cancer patients with peritoneal metastases we are expecting approximately 15,000 new patients per year in the United States. Certainly, that will require many additional centers of excellence for CRS plus HIPEC."
Referring to PMP in particular, Dr H Sugarbaker tells PMP Pals, "Now there are are many 10-year and 20-year survivors of this rare disease. Definitely, a new chapter in the medical history of pseudomyxoma peritonei has been written."
Click here for more information about Dr Paul H Sugarbaker's research.
Gabriella conducted this interview with Dr Paul H Sugarbaker on March 30, 2012.
Dr Paul Sugarbaker brings HIPEC to Mexico
Are you scheduled for surgery with Dr Sugarbaker?
Pal Mentors are specifically screened, selected and trained to mentor those patients preparing for and recuperating from medical treatment.
The "Pal Mentors" listed below, have all successfully recuperated from treatment under the care of Dr Sugarbaker; most have been disease free for 10+ years!
Join the PMP Pals' Network and begin communicating with these successful "veterans" of treatment from Dr Sugarbaker!
The "Pal Mentors" listed below, have all successfully recuperated from treatment under the care of Dr Sugarbaker; most have been disease free for 10+ years!
Join the PMP Pals' Network and begin communicating with these successful "veterans" of treatment from Dr Sugarbaker!
Jeanne has been cancer free for more than a decade!
Mary Anne has been cancer free for 10+ years!
Brian gives the V for Victory over cancer! He's been cancer free over a decade!
Merrily enjoys life and has been cancer free 10+ years!
Evan has been cancer free for more than a decade!
Mary is smiling because she has been cancer free for more than 10 years!
Bud & his wife are global travelers since his successful surgery with Dr Sugarbaker!
Ken celebrates life every day!
Here's what Dr Sugarbaker's patients say about the PMP Pals' Network!
Merrily and Mary Anne are successful "veterans" of surgery with Dr Sugarbaker who met through the PMP Pals' Network!
"Thank you for the information that you have shared with my family. Your words are courageous and much appreciated. As rare as this disease seems to be, now I know that I am not in this alone." KB, USA, patient of Dr. Paul H Sugarbaker
"Thank you for your support and assistance during my recuperation from surgery. This website is an outstanding resource and your handbooks are immensely helpful!" DN, patient of Dr. Paul H Sugarbaker
"My spirits are always 100 points higher after I talk with you. Thank you for the referrals to specialists, and other information that helps me through my next hurdle!" RR, USA, patient of Dr. Paul H Sugarbaker
"Thank you for all your extra efforts for PMP Pals! The information you provide to patients and concerned caregivers is given with thoughtful consideration and without bias to physician, hospital, or suggested method of treatment. What a pro!" MS, USA, patient of Dr. Paul H Sugarbaker
"Thank you for the privilege of letting me extend my hand to those like the PMP Pals that extended their hands to me after my surgery. I cannot say how much their support and yours meant to me when I needed you!" CB, USA, pt of Dr Paul Sugarbaker
"I want to thank you for ALL you do on a daily basis to assist us. Your knowledge, support and caring ways are truly a gift." AB, USA, pt of Dr Paul Sugarbaker
"I believe that PMP Pals are the main reason I am still alive today." WB, USA, pt of Dr Paul Sugarbaker
"You helped me enormously when I was a patient in the Washington Hospital Center!" LK, patient of Dr. Paul H Sugarbaker
"What a thoughtful web page! Most informative and useful!" EB, USA, Patient of Dr. Paul H Sugarbaker
"Thank you for everything you do for all of us every single day! You are an inspiration to me!" CC, patient of Dr Paul H Sugarbaker
Dr Paul Sugarbaker Explains Surgical Abbreviations
Dr Paul Sugarbaker Provides List of Abbreviations for Surgery and HIPEC
Thank you to Dr Paul Sugarbaker for providing the PMP Pals' Network with this listing of abbreviations commonly used for the treatment of Peritoneal Surface Malignancies.
For additional information see our Appendix Cancer Glossary.
1. CS – Chemosurgery (most general abbreviation includes CRS, HIPEC, EPIC and ABC)
2. HIPEC – Hyperthermic intraperitoneal chemotherapy
3. HIPEC + 5FU – Hyperthermic intraperitoneal chemotherapy plus intravenous 5-fluorouracil
4. HIPEC + IFO – Hyperthermic intraperitoneal chemotherapy plus intravenous ifosfamide
5. EPIC – Early postoperative intraperitoneal chemotherapy usually 5-FU or paclitaxel
6. ABC – Adjuvant bidirectional chemotherapy
7. CRS – Cytoreductive surgery
8. CCRS – Complete cytoreductive surgery
9. PM – Peritoneal metastases (should replace PC)
10. PC – Peritoneal carcinomatosis
11. POC – Perioperative chemotherapy
12. LM – Liver metastases
13. LNM – Lymph node metastases
14. LR – Local-regional
15. IP port – Intraperitoneal port used for ABC
16. Tenckhoff catheter – Temporary catheter used to deliver EPIC
Dr Paul Sugarbaker's Research Publications
Click here for the most recent, among hundreds of, Dr Sugarbaker's research publications
- Getting Chemotherapy into the Cancerous Tissue
Volume 15, Number 11 / November, 2008
View abstract | View full article on SpringerLink | View full article PDF - Decreasing the Risk of a Treatment Expands Its Indications
Volume 12, Number 11 / November, 2005
View abstract | View full article on SpringerLink | View full article PDF - Clinical Research to Standard of Care: When Does the Transition Occur?
Volume 10, Number 8 / September, 2003
View abstract | View full article on SpringerLink | View full article PDF - Results of Treatment of 385 Patients With Peritoneal Surface Spread of Appendiceal Malignancy
Volume 6, Number 8 / December, 1999
View abstract | View full article on SpringerLink | View full article PDF - Reported Impact of Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy on Systemic Toxicity
Volume 15, Number 6 / June, 2008
View abstract | View full article on SpringerLink | View full article PDF - Comprehensive Management of Disseminated Colorectal Cancer
Volume 15, Number 12 / December, 2008
View abstract | View full article on SpringerLink | View full article PDF - Five Reasons Why Cytoreductive Surgery Plus Hyperthermic Intraperitoneal Chemotherapy Must be Regarded as the New Standard of Care for Diffuse Malignant Peritoneal
Volume 17, Number 6 / June, 2010
View abstract | View full article on SpringerLink | View full article PDF - Erratum to: Five Reasons Why Cytoreductive Surgery Plus Hyperthermic Intraperitoneal Chemotherapy Must be Regarded as the New Standard of Care for Diffuse Malignant Peritoneal Mesothelioma
Volume 18, Number 3 / December, 2011
View abstract | View full article on SpringerLink | View full article PDF - Parietal Peritonectomy
Volume 19, Number 4 / April, 2012
View abstract | View full article on SpringerLink | View full article PDF - Discordant Histology of Primary Appendiceal Adenocarcinoid Neoplasms with Peritoneal Dissemination
Volume 15, Number 5 / May, 2008
View abstract | View full article on SpringerLink | View full article PDF
Systematic Review on the Efficacy of Cytoreductive Surgery Combined With Perioperative Intraperitoneal Chemotherapy for Peritoneal Carcinomatosis From Colorectal Carcinoma
by Tristan D. Yan, Deborah Black, Renaldo Savady, Paul H. Sugarbaker
Sources: Peritoneal Surface Malignancy Program, Washington Cancer Institute, Washington, DC; and the School of Public Health and Community Medicine, The University of New South Wales, Sydney, Australia.Address reprint requests to Paul H. Sugarbaker, MD, 106 Irving St, NW, Suite 3900N, Washington, DC, 20010; e-mail: Paul.Sugarbaker@medstar.net
Support research by Dr Paul H Sugarbaker
The Foundation for Applied Research in Gastrointestinal Oncology (FARGO) is a non-profit 501 (c)(3) organization that promotes research, education and patient care in gastrointestinal oncology. FARGO's primary objective is to facilitate the transfer of basic science research into innovations in patient care. The responsibilities of FARGO include financial support, administrative support, and space for continued progress in the prevention and treatment of gastrointestinal cancer.
FARGO was created in 1993 by Dr. Paul Sugarbaker and the FARGO Board of Directors
Donations to FARGO are tax deductible and can be made to:
FARGO
c/o Washington Hospital Center
106 Irving St., NW Suite 3900
Washington, D.C. 20010
Schedule a Consultation with Dr Sugarbaker!
Paul H. Sugarbaker, MD, FACS, FRCS
Section Director, Program in Peritoneal Surface Malignancy
MedStar Washington Hospital Center
106 Irving St., NW, POB 3900
Washington, DC 20010
Phone: (202) 877-3908
Fax: (202) 877-8602
Email: Paul.Sugarbaker@medstar.net
Dr Paul Sugarbaker will not retire!
PMP Pals' Network
Visitors to www.pmppals.org are encouraged to discuss publications and information contained herein with their licensed, professional healthcare providers. The information provided on www.pmppals.org is not intended as a replacement for licensed, professional medical or legal advice.
Please respect your fellow patients and caregivers by not copying or cutting and pasting any pages from this website onto yours.
The PMP Pals Network is a volunteer patient advocacy program. We support the services that we provide, including this web page, as volunteers and through subscriptions to our publications.
We neither solicit nor receive funds from pharmaceutical companies or healthcare providers, thus maintaining our dedication to serving as patient advocates. Website design by Gabriella Graham. Updated 08.10.12
